Antidepressant therapy in functional gastrointestinal disorders;Tratamiento con antidepresivos en los trastornos funcionales digestivos

Gastroenterologia y Hepatologia

Volumn 28, Issue 8, 2005, Pages 485-492

  Bixquert Jimenez M ^a,c   Bixquert Pla, L ^b  

^a HOSPITAL ARNAU DE VILANOVA   (Spain)

^b HOSPITAL LLUÍS ALCANYÍS   (Spain)

^c NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; AMOXAPINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; CLONIDINE; DESIPRAMINE; DOXEPIN; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MAPROTILINE; MIANSERIN; MIRTAZAPINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NIALAMIDE; NORADRENALIN UPTAKE INHIBITOR; NORTRIPTYLINE; PAROXETINE; PHENELZINE; PSYCHOTROPIC AGENT; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; UNINDEXED DRUG; VENLAFAXINE;

ANALGESIC ACTIVITY; ANTICHOLINERGIC EFFECT; ANXIETY; CARDIOTOXICITY; CHRONIC PAIN; DEPRESSION; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE ASSOCIATION; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPOTENSION; IRRITABLE COLON; NEUROMODULATION; NEUROSIS; REVIEW; THORAX PAIN;

EID: 27444442045     PISSN: 02105705     EISSN: None     Source Type: Journal    
DOI: 10.1157/13079000     Document Type: Article

References (38)

1. Bixquert M, Mearin F, Ponce J. Decisiones en... trastornos funcionales digestives. Madrid: Emisa; 1995.
2. Erckenbrecht JF. Motility disorders of the gastrointestinal tract. Highligths of the 1st European Postraduate Course on Gastrointestinal Motility 10 to 13 June in Utrecht. Z Gastroenterol. 1993;31 Suppl 1:1-18.
3. Drossman DA, Creed FH, Orden KW, et al. Psychosocial aspects of the functional gastrointestinal disorders. Gut. 1999;45 Suppl 11:1125-30.
4. Drossman DA, Corazziari E, Talley NJ, Thompson WG, Whitehead WE, editors. Rome II. The functional gastrointestinal disorders. 2nd ed. McLean VA: Degnon Ass.; 2000.
5. Bonaz B. Visceral sensitivity perturbations integration in the brain-gut axis in functional digestive disorders. J Physiol Pharmacol. 2003;54 Suppl 4:27-42.
6. Silverman DHS, Munakata JA, Ennes H, et al. Regional cerebral activity in normal and pathological perception of visceral pain. Gastroenterology. 1997;12:64-72.
7. a ed. Madrid: Adis Internacional; 2004. p. 664-73.
8. Raine R, Haines A, Sensky T, et al. Systematic review of mental and health interventions for patients with common somatic symptoms: can research evidence from secondary care be extrapolated to primary care? BMJ. 2002;325:1082-92.
9. 2A-adrenoceptors. Jpn J Pharmacol. 2000;82:130-7.
10. Pasricha PJ. Approach to the patient with abdominal pain. En: Yamada T, editor. Textbook of Gastroenterology. 4th ed. Filadelfia: Lippincott, Williams & Wilkins; 2003. p. 781-801.
11. Castell DO, Katz PO. Approach to the patient with unexplained noncardiac chest pain. En: Yamada T, editor. Textbook of Gastroenterology. 4th ed. Filadelfia: Lippincott, Williams & Wilkins; 2003. p. 692-8.
12. Bennett J. ABC of the upper gastrointestinal tract. Oesophagus: atypical chest pain and motility disorders. BMJ. 2001;323:791-4.
13. Peghini PI, Katz PO, Castell DO. Imipramine decreases oesophageal pain perception in human male volunteers. Gut. 1998; 42:807-13.
14. Clouse RE, Lustman PJ, Eckert TC, Ferney DM, Griffith LS. Low-dose trazodone for symptomatic patients with esophageal contraction abnormalities. A double-blind, placebo-controlled trial. Gastroenterology. 1987;92:1027-36.
15. Cannon RO 3rd, Quyyumi A, Mincemoyer R, et al. Imipramine in patients with chest pain despite normal coronary angiograms. N Engl J Med. 1994;330:1411-7.
16. Prakash C, Clouse R. Long-term outcome from tricyclic antidepressant treatment of functional chest pain. Dig Dis Sci. 1999;44:2373-9.
17. Grupo de trabajo de la Guía de Práctica Clínica sobre Dispepsia. Manejo del paciente con Dispepsia. Asociación Española de Gastroenterología, Sociedad Española de Medicina de Familia y Comunitaria y Centro Cochrane Iberoamericano. Programa de Elaboración de Guías de Práctica Clínica en Enfermedades Digestivas, desde la Atención Primaria a la Especializada: 3. Barcelona: SCM; 2003.
18. Tanum L, Malt UF. A new pharmacologic treatment of functional gastrointestinal disorders: a double-blind placebo-controlled study with mianserin. Scand J Gastroenterol. 1996;31:318-25.
19. Mertz H, Fass R, Kodner A, et al. Effect of amitriptyline on symptoms, sleep, and visceral perception in patients with functional dyspepsia. Am J Gastroenterol. 1998;93:160-5.
20. Jackson JL, O'Malley PG, Tomkins G, et al. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med. 2000;108:65-72.
21. Jones MP. Evaluation and treatment of dispepsia. Postgrad Med J. 2003;79:25-9.
22. Talley NJ. Update on the role of drug therapy in non-ulcer dispepsia. Rev Gastroenterol Disord. 2003;3:25-30.
23. Delgado-Aros S. Intervenciones psicológicas y antidepresivos en la dispepsia funcional. GH Continuada. 2004;3:120-4.
24. Azpiroz F. Tratamiento del dolor abdominal crónico. En: Ponce J, editor. AEG: tratamiento de las enfermedades gastroenterológicas. Barcelona: Doyma, 2001; p. 417-23.
25. Jones J, Boorman J, Cann P, et al. British Society of Gastroenterology guidelines for the management of the irritable bowel sindrome. Gut. 2000;41 Supl 11:1-19.
26. Drossman DA. Approach to treatment of irritable bowel syndrome. X Curso de Postgraduados: Avances en Gastroenterología y Hepatología. Madrid: Edimsa; 2003. p. 59-67.
27. Greenbaum DS, Mayle JE, Vanegeren LE, et al. Effects of desipramine on irritable bowel syndrome compared with atropine and placebo. Dig Dis Sci. 1987;32:257-66.
28. Clouse RE, Lustran PJ, Geisman RA, Alpers DH. Antidepressant therapy in 138 patients with irritable bowel syndrome: a five-year clinical experience. Aliment Pharmacol Ther. 1994;8:409-16.
29. Klein KB. Controlled treatment trials in the irritable bowel syndrome. Gastroenterology. 1988;95:232-41.
30. Akehurst R, Kaltenhaler E. Treatment of irritable bowel syndrome: a review of randomized clinical trials. Gut. 2001;48:272-82.
31. Jailwala J, Imperiale TF, Kroenke K. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann Intern Med. 2000;133:136-47.
32. Coulie B, Camilleri M. New therapies for functional bowel diseases. Curr Gastroenterol Rep. 2000;2:355-63.
33. Clouse RE. Therapy Update: Antidepressants for irritable bowel syndrome. Gut. 2003;52:598-9.
34. Valenzuela J, Alvarado J, Cohen H, et al. Un consenso latino-americano sobre el síndrome del intestino irritable. Gastroenterol Hepatol. 2004;27:325-43.
35. Moreno E, Antón MD, Del Val A. Tratamiento del síndrome del intestino irritable. Med Clin Monogr (Barc). 2003;4:41-7.
36. Creed F, Fernandes L, Guthrie E, et al. The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology. 2003;124:303-17.
37. Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology. 2002;123:2108-31.
38. Drossman DA, Creed FH, Fava GA, et al. Psychosocial aspects of the functional gastrointestinal disorders. Gastroenterol Int. 1995;8:47-90.